Skip to main content

Table 4 Characteristic totals for co-colonization at hospital admission

From: Risk factors for Candida colonization and Co-colonization with multi-drug resistant organisms at admission

Characteristic N Total (SDӨ,%) With Co-col (SDӨ, %) Without Co-col (SDӨ, %)
Age (avg., yr) 491 56.4 (15.1) 58.9 (17.4) 56.3 (15.0)
Body mass index (avg.) 486 28.6 (8.3) 28.9 (9.2) 28.6 (8.2)
Gender (male) 492 275 (55.9 %) 15 (5.8 %) 260 (94.5 %)
Gender (female) 492 217 (44.1 %) 18 (8.3 %) 199 (91.7 %)
Ambulatory Status (ambulatory) 492 353 (71.7 %) 21(5.9 %) 332 (94.1 %)
Alcohol use 492 154 (31.3 %) 12 (7.8 %) 142 (92.2 %)
Surgery 492 69 (14.0 %) 2 (2.9 %) 67 (97.1 %)
Coronary artery disease 492 109 (22.2 %) 8 (7.3 %) 101 (92.7 %)
Chemotherapy 492 62 (12.6 %) 3 (4.8 %) 59 (95.2 %)
Lung Disease 492 62 (12.6 %) 6 (9.7 %) 56 (90.3 %)
Hypertension 492 291 (59.1 %) 18 (6.2 %) 273 (93.8 %)
Immunosuppression 492 192 (39.0 %) 10 (5.2 %) 182 (94.8 %)
Malnutrition 491 77 (15.7 %) 14 (18.2 %) 63 (81.8 %)
Cancer 491 152 (31.0 %) 9 (5.9 %) 143 (94.1 %)
Peripheral vascular disease 492 35 (7.1 %) 3 (8.6 %) 32 (91.4 %)
Renal Failure 492 106 (21.2 %) 11 (10.4 %) 95 (89.6 %)
Steroids 492 172 (35.0 %) 9 (5.2 %) 163 (94.8 %)
Abdominal drain 491 21 (4.3 %) 1 (4.8 %) 20 (95.2 %)
Non-insulin dependent diabetes 492 50 (10.2 %) 4 (8.0 %) 46 (92.0 %)
Insulin-dependent diabetes 491 105 (21.4 %) 8 (7.6 %) 97 (92.4 %)
Foley Catheter 492 116 (24.2 %) 12 (10.3 %) 104 (89.7 %)
Hemodialysis 490 29 (5.9 %) 3 (10.3 %) 26 (89.7 %)
Neutropenia 490 14 (2.9 %) 1 (7.1 %) 13 (92.9 %)
Open wound 486 101 (20.8 %) 10 (9.9 %) 91 (90.1 %)
Surgical wound 490 76 (15.5 %) 6 (7.9 %) 70 (92.1 %)
Transplant 490 111 (22.7 %) 4 (3.6 %) 107 (96.4 %)
Vascular catheter 489 462 (94.5 %) 31 (6.7 %) 431 (93.3 %)
Vent support 492 19 (3.9 %) 2 (10.5 %) 17 (89.5 %)
History of Candida 492 56 (11.4 %) 5 (8.9 %) 51 (91.1 %)
History of MRSAӨ 492 28 (5.7 %) 8 (28.6 %) 20 (71.4 %)
History of VREӨ 492 8 (1.6 %) 1 (12.5 %) 7 (87.5 %)
History of GNӨ 492 41 (8.3 %) 4 (9.8 %) 37 (90.2 %)
Days in hospital in 2 years. prior to admit (avg., days) 489 34.1 (108.8) 34.1 (40.5) 34.1 (112.1)
Days in ICU in 2 years. prior to admit (avg., days) 492 1.5 (4.9) 4.5 (9.6) 1.3 (4.3)
Aminoglycosidesa 492 11 (2.2 %) 1 (9.1 %) 10 (90.9 %)
Carbapenemsa 492 4 (0.8 %) 2 (50.0 %) 2 (50.0 %)
1st Gen Cephalosporinsa 492 41 (8.3 %) 3 (7.3 %) 38 (92.7 %)
3rd Gen Cephalosporinsa 492 34 (6.9 %) 5 (14.7 %) 29 (85.3 %)
4th Gen Caphalosporinsa 492 12 (2.4 %) 1 (8.3 %) 11 (91.7 %)
Glycopeptides 492 32 (6.5 %) 5 (15.6 %) 27 (84.4 %)
Lincosamidesa 492 23 (4.7 %) 1 (4.3 %) 22 (95.7 %)
Macrolidesa 492 29 (5.9 %) 5 (17.2 %) 24 (82.8 %)
Penicillinsa 492 26 (5.3 %) 4 (15.4 %) 22 (84.6 %)
Penicillin Combinationsa 492 57 (11.6 %) 5 (8.8 %) 52 (91.2)
Fluoroquinolonesa 492 101 (20.5 %) 10 (9.9 %) 91 (90.1 %)
Sulfonamidesa 492 62 (12.6 %) 1 (1.6 %) 61 (98.4 %)
Drugs against mycobacteriaa 492 5 (1.0 %) 2 (40.0 %) 3 (60.0 %)
Other antibioticsb 492 21 (4.3 %) 5 (23.8 %) 16 (76.2 %)
  1. Ө SD standard deviation, MRSA Methicillin resistant Staphylococcus aureus, VRE Vancomycin resistant Enterococcus, RGN antibiotic resistant Gram-negative organisms
  2. All variables are dichotomous, yes vs. no, unless otherwise stated
  3. aAntibiotic use occurred prior to admission to hospital
  4. bOther antibiotics included use of either Metronidazole, Dapsone or Linezolid